Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110695 · ClinicalTrials.gov registry record · Phase 2
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer
A Phase 2 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00110695 is a Phase 2 study that has completed, run by NSABP Foundation. The registered enrollment target is 66 participants.
The verdict
NCT00110695, a Phase 2 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how breast cancer tumors respond to a drug called Abraxane followed by a combination of 3 chemotherapy drugs commonly used for breast cancer.
Interventions
- DRUG Nanoparticle albumin bound paclitaxel followed by FEC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110695
The ClinicalTrials.gov registry entry for NCT00110695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nanoparticle albumin bound paclitaxel followed by FEC is the first listed.
NCT00110695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110695 about?
NCT00110695 is a clinical study titled "Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer". The purpose of this study is to learn how breast cancer tumors respond to a drug called Abraxane followed by a combination of 3 chemotherapy drugs commonly used for breast cancer.
What is the current status of trial NCT00110695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2005-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00110695?
The interventions under investigation include: Nanoparticle albumin bound paclitaxel followed by FEC (DRUG).
Who is sponsoring clinical trial NCT00110695?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.